It was probably not a coincidence that the inflammasome activation triggered by mild COVID-19 resulted in such a devastating outcome in this patient, considering the patient’s background of chronic cholestasis and potentially low-grade NLRP3 activity in association with PBC [2]. The gene discussed is NLRP3; the disease is COVID-19.